| Cash flow (USD) | Q4 2026 ended Jun 30, 2026 | Q3 2026 ended Mar 31, 2026 | Q2 2026 ended Dec 31, 2025 | Q1 2026 ended Sep 30, 2025 | Q4 2025 ended Jun 30, 2025 | Q3 2025 ended Mar 31, 2025 | Q2 2025 ended Dec 31, 2024 | Q1 2025 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | -4.57M | -6.36M | -3.09M | -4.84M | -4.07M | -54.07M | -430.2K | -354.3K |
| Depreciation and amortization | 327 | 316 | 229 | 125 | 0 | |||
| Stock-based compensation | 1.23M | 5.35M | 1.79M | 3.02M | 3.12M | 52.84M | ||
| Cash from operations | -1.60M | -1.14M | -999.1K | -1.94M | -92.2K | -96.2K | 18.7K | -235.5K |
| Capital expenditure | -21 | -154 | -2.3K | -2.5K | ||||
| Free cash flow | -1.60M | -1.14M | -1.00M | -1.94M | ||||
| Cash from investing | -21 | -154 | -2.3K | -2.5K | ||||
| Net debt issued | 0 | 0 | 0 | -671.8K | -24.4K | 0 | ||
| Cash from financing | 1.98M | 981.6K | 965.1K | 2.53M | 72.8K | 147.5K | 54.8K | 215.7K |
| Net change in cash | 388.3K | -117.5K | -41.5K | 590.6K | -38.7K | 36.1K | 5.4K | -11.8K |
From Propanc Biopharma, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.